Industry Innovators: APAC's Sharp Advanced Therapeutics Edge

The Asia‑Pacific region has rapidly evolved into a powerhouse for advanced therapeutics, reshaping expectations for how development and commercialization can be executed at scale. Across key markets, organizations are adopting more agile clinical strategies, investing in next‑generation manufacturing capacity, and aligning early with regulators to accelerate progress from early research to patient access. Roman Necina, VP and GM of Viral Vector at Cytiva, offers an inside look at the specific shifts enabling this momentum—from streamlined regulatory pathways to a more collaborative approach between industry and government. His perspective highlights how APAC is not only supporting regional growth but also influencing global standards for speed, quality, and innovation in advanced therapies.

Explore the full article to understand the practices redefining the competitive landscape and why global developers are paying close attention.